Highest-materiality recent filing
Avantor Q1 net sales flat YoY; GAAP EPS $0.06, adj. EPS $0.17; reaffirms FY 2026 guidance
Net sales $1,581M flat YoY; organic sales down 4.1% due to FX headwind of 4.1%.
Avantor names Ludovic Brellier EVP Bioscience & Medtech Products; Gourdier to depart by Dec 2026
Ludovic Brellier appointed EVP, Bioscience & Medtech Products and Chief Transformation Officer effective May 1, 2026.
Avantor CFO Brent Jones to depart by June 24; interim CFO named
CFO R. Brent Jones resigns to join a non-life-sciences company; effective on or before June 24, 2026.
Avantor posts $530M net loss in 2025; Q4 organic sales down 4%; Revival program launched
Q4 net sales $1.66B, organic decline 4%; net income dropped to $52M from $500M; GAAP EPS $0.08.
Avantor Q3 net loss $712M on $785M goodwill impairment; sales down 5.3% YoY
Net sales $1.62B, down 5.3% YoY; organic sales decline 4.7%.
Avantor chairman Jonathan Peacock to step down Dec 31, 2025; Gregory Summe to succeed
Jonathan Peacock informed Avantor he will step down as chairman and board member effective December 31, 2025.
Avantor amends credit agreement, adds $1.4B RCF and €950M term loans; redeems €650M notes
New $1.4B revolving credit facility (RCF) maturing Oct 2030, plus €400M TLA and €550M TLB (TLB matures Oct 2032).
Avantor Q2 net sales $1.68B flat organic; GAAP EPS $0.09; names new CEO
Net sales $1.68B (-1% reported, flat organic); net income $64.7M vs $92.9M a year ago.
Avantor names Emmanuel Ligner as President and CEO effective August 18, 2025
Ligner succeeds Michael Stubblefield, who steps down as previously announced.
Avantor CEO Michael Stubblefield to step down upon successor appointment
Stubblefield to step down as CEO and from board; will remain non-executive advisor until Feb 28, 2026.
Avantor Q1 net sales down 6% to $1.58B; organic decline 2%; adjusted EPS $0.23
Net sales $1,581.4M (-6% reported, -2% organic); net income $64.5M ($0.09 GAAP EPS); adjusted EPS $0.23.
Avantor Q4 organic growth 1%, adjusted EPS $0.27; full-year adjusted EPS $0.99
Q4 net sales $1.69B, down 2% reported; organic growth 1% with bioprocessing up high-single digits.
Avantor Q3 net sales $1.71B (-0.3%), net income $57.8M, raises FCF guidance
Net sales $1,714.4M, down 0.3% reported; organic decline 0.7%; currency tailwind of 0.4%.
Avantor reports Q2 net sales down 2.4% to $1.70B; GAAP EPS $0.14, adjusted $0.25
Net sales $1.70B, down 2.4% YoY; organic decline 2.0% after FX impact.
Avantor Q1 net sales fall 5.6% to $1.68B; net income down 50% to $60M
Net sales $1.68B, -5.6% YoY; organic decline 6.3%. Net income $60M vs $121.5M prior year.
Avantor refinances $772M term loans at lower rate; former EVP to advise
Refinanced $772.4M Incremental B-6 Dollar Term Loans at SOFR + 2.00% (down from +2.25% on prior loans).
Avantor Q4 revenue $1.72B, decline 4%; adjusted EPS $0.25; new segment structure disclosed
Q4 net sales $1.72B, down 4.0% YoY; core organic decline 4.8%; Q4 GAAP EPS $0.15, adjusted EPS $0.25.
New segments: Laboratory Solutions (~$4.7B revenue) and Bioscience Production (~$2.3B revenue), effective Q1 2024.
Avantor Q3 2023 net sales $1.72B (-7.3%); GAAP EPS $0.16, adjusted EPS $0.25
Net income $108.4M, adjusted net income $171.6M; free cash flow $193M, operating cash flow $230.7M.
Avantor Q2 net sales $1.74B, down 8.7%; GAAP EPS ($0.01), adjusted EPS $0.28; net loss $7.3M
Net sales $1.74B, core organic decline 6.5%; net loss $7.3M vs income $187.4M YoY.
Avantor appoints R. Brent Jones as CFO effective August 7, 2023
R. Brent Jones named EVP and CFO, effective Aug 7; replaces Thomas Szlosek who departs Aug 4.
Avantor CFO Thomas Szlosek to depart Aug 2, 2023; FY2023 guidance reaffirmed
CFO Thomas Szlosek resigns effective August 2, 2023 to join a company outside life sciences.
Avantor Q1 net sales $1.78B, down 8.7% YoY; adjusted EPS $0.29
Net sales $1.78B, down 8.7% YoY; core organic sales decline 1.8% (ex-COVID).
Avantor Q4 net sales down 5.9% to $1.80B; core organic growth +2.7%; adj. EBITDA margin 20.0%
Q4 GAAP diluted EPS $0.21; adjusted EPS $0.32; net income $141.7M vs $94.0M a year ago.
Net sales $1.86B (+1.2% reported); core organic growth 7.8%; net income $167.0M.
Avantor Q2 beats: EPS $0.37 adjusted, revenue $1.91B, core organic growth 6.4%
Net sales $1.91B (+2.8% reported; core organic +6.4%); adjusted EBITDA $404.1M (+10.2%), margin 21.2% (+140bps).
Avantor Q1 2022: Net sales $1.95B, adj EPS $0.38, raises full-year guidance
Net sales $1.95B, organic growth 5.1%; net income $190.4M vs $164.0M prior year.
Michael Stubblefield and Avantor, Inc. (the “Company”) agreed to initiate a leadership transition and Mr. Stubblefield agreed to step down from his role as Director, President and Chief Executive Officer of the Company, effective upon the appointment of his successor.
On January 6, 2025, Avantor, Inc. (the “Company”) was notified by Jim Bramwell, its Executive Vice President, Sales and Customer Excellence, of his intention to retire from the Company on or around June 30, 2025, and pursue a full-time service opportunity within his faith.
On November 4, 2024, the Board of Directors (the “Board”) of Avantor, Inc. (the “Company”), upon the recommendation of its Nominating and Governance Committee, elected Dame Louise Makin DBE as a director with an initial term expiring on the date of the Company’s 2025 Annual Meeting of Stockholders.
the Company and Frederic Vanderhaegen, the Company’s former Executive Vice President, Europe, and a named executive officer in the Company’s definitive proxy statement on Schedule 14A filed on March 29, 2024, agreed that Mr. Vanderhaegen would depart from the Company on June 30, 2024.
On June 21, 2024, Avantor, Inc. (the “Company”) announced that Randy Stone, who had served as the Executive Vice President, Laboratory Solutions, would be leaving the Company effective June 30, 2024.
on December 1, 2023, the Company informed each of Sheri Lewis, the Company’s Executive Vice President, Global Supply Chain, and Frederic Vanderhaegen, the Company’s Executive Vice President, Europe, that each would depart from the Company in 2024 after supporting the Company’s transition to its new operating model.
on December 1, 2023, the Company informed each of Sheri Lewis, the Company’s Executive Vice President, Global Supply Chain, and Frederic Vanderhaegen, the Company’s Executive Vice President, Europe, that each would depart from the Company in 2024 after supporting the Company’s transition to its new operating model.
On September 26, 2023, Avantor, Inc. (the “Company”) announced that Dr. Gerard Brophy, the Company’s Executive Vice President, Biopharma Production and a named executive officer in the Company’s definitive proxy statement on Schedule 14A filed on March 31, 2023, will be stepping down from that position on October 2, 2023, and retiring from the Company effective February 29, 2024.
On July 13, 2023, Avantor, Inc. (the “Company”), announced the appointment of R. Brent Jones as Executive Vice President and Chief Financial Officer, effective as of August 7, 2023.
the Company’s current Executive Vice President and Chief Financial Officer, Thomas Szlosek, whose resignation was previously announced, has agreed to continue in his position through August 4, 2023.
On May 9, 2023, Mr. Thomas A. Szlosek notified the Company of his decision to resign as the Company’s Executive Vice President and Chief Financial Officer (“CFO”), effective as of August 2, 2023, to join a company outside the life sciences industry.
Effective as of November 16, 2022, Matt Holt retired from the Board of Directors (the “Board”) of Avantor, Inc. (the “Company”).
Max materiality 0.85 · Median 0.60 · Most common event leadership